MediWound Ltd.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $170.9M
- Price
- $13.15
- % Change (Daily % change from the live per-ticker quote feed.)
- -2.66%
- Volume
- 58.8K
About
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Quick stats
Shares outstanding13.0M
Computed float11.4M
Float / shares87.4%
Cash runway (months)8.7
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001593984
Websitehttps://www.mediwound.com
AI Summary
AI-generated1/12
standardbullishoperations update
MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid®
MediWound received an additional $3.3 million in non-dilutive funding from the U.S. Department of War to advance a room-temperature-stable formulation of NexoBrid as a non-surgical debridement solution for battlefield burn care.
The award raises the total program budget to $21.8 million and supports development through an IND submission to the FDA, with work focused on completing CMC, establishing in-house cGMP manufacturing, and producing clinical batches.
The program falls within MediWound's existing North American license agreement with Vericel, which holds exclusive commercial and development rights to NexoBrid in the region.
Red flags
- Government funding carries termination-for-convenience, modification, non-renewal, and budget-sequestration risk (flagged in the release's own forward-looking statements)
- Award funds pre-IND development only; clinical advancement still requires FDA IND acceptance and the company has disclosed a need for additional financing